Savchuk Nikolay 4

What Happened Nikolay Savchuk, Chief Operating Officer of Traws Pharma, received a grant of 93,000 stock options on July 9, 2026. The Form 4 lists the transaction value as $0.00 because this is an option award (a derivative), not an open-market purchase or sale; options do not represent immediate share ownership or cash proceeds.

Key Details

• Transaction date: 2026-07-09; Form 4 filed: 2026-07-15 (appears to be filed late vs. the usual 2-business-day Form 4 deadline).
• Security: stock options (derivative); reported acquisition amount: 93,000 options; consideration reported: $0.00.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: options were awarded under the Issuer's 2021 Incentive Compensation Plan; the award vests 100% on the first anniversary of the grant date. The compensation committee that approved the award is comprised of independent directors.

Context This filing documents an equity compensation grant to an executive rather than a purchase or sale. Options can provide future upside if the stock price rises after vesting and exercise; they require exercising to convert into shares. Awards like this are common for executive pay and do not by themselves indicate buying or selling sentiment.